Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188015 | 0.92 | RAB9A (0.58) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL9265040 | 0.85 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL6707186 | 0.85 | RAB9A (0.79) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL19445791 | 0.84 | RAB9A (0.72) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL23360958 | 0.83 | L3MBTL1 (0.64) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL4195062 | 0.82 | MEN1 (0.64) | NPC1SMN1; SMN2PKMALDH1A1HTT | |
| SCHEMBL14288607 | 0.81 | FAAH (0.62) | RAB9AALDH1A1 | |
| SCHEMBL27748372 | 0.79 | L3MBTL1 (0.67) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL7233864 | 0.79 | RAB9A (0.68) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL3771488 | 0.79 | RAB9A (0.68) | RAB9ANPC1L3MBTL1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | claimed |
| EP-2023930-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008020866-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON | 2008-02-21 | — | — | WO | disclosed |
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155707-A1 | IONIZABLE INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, NAAA | RAB9A 2583/4885NPC1 583/4885L3MBTL1 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.